Margaret B Nolan
Overview
Explore the profile of Margaret B Nolan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nolan M, Asche S, Barton K, Benziger C, Ekstrom H, Essien I, et al.
Am J Prev Med
. 2024 Nov;
68(3):429-436.
PMID: 39615766
Introduction: Intellectual and Developmental Disabilities (IDD) have been associated with high cardiometabolic risk in adults, but there is little data on youth. This study describes the prevalence of cardiometabolic risk...
2.
Nolan M, Chrenka E, DeSilva M
JAMA Netw Open
. 2024 Oct;
7(10):e2437388.
PMID: 39361282
Importance: Disparities in COVID-19 vaccination rates by race and ethnicity are well documented. Less is known about primary language and COVID-19 vaccine uptake. Objective: To describe the time to COVID-19...
3.
Nolan M, Chrenka E, Walker P, Steiner A, Rodrigues K, Michel J, et al.
Vaccine
. 2024 Apr;
42(12):3115-3121.
PMID: 38604910
Background: In the United States (US), COVID-19 vaccination rates among non-US-born individuals (i.e., refugees, immigrants, and migrants [RIM]) are variable. Understanding baseline COVID-19 vaccine coverage among these populations and determining...
4.
Omar S, Whitfield M, Nolan M, Ngom J, Ismail N, Warren R, et al.
J Antimicrob Chemother
. 2023 Dec;
79(2):211-240.
PMID: 38134888
Background: Non-tuberculous mycobacteria (NTM) infections are increasing in incidence and associated mortality. NTM are naturally resistant to a variety of antibiotics, complicating treatment. We conducted a literature assessment on the...
5.
Nolan M, Nolan M, Piasecki T, Fiore M
Chest
. 2023 Feb;
163(6):1390-1394.
PMID: 36731788
No abstract available.
6.
Hohl S, Matulewicz R, Salloum R, Ostroff J, Baker T, Schnoll R, et al.
J Clin Oncol
. 2022 Dec;
41(15):2756-2766.
PMID: 36473135
Purpose: Quitting smoking improves patients' clinical outcomes, yet smoking is not commonly addressed as part of cancer care. The Cancer Center Cessation Initiative (C3I) supports National Cancer Institute-designated cancer centers...
7.
Fiore M, Smith S, Adsit R, Bolt D, Conner K, Bernstein S, et al.
PLoS One
. 2022 Sep;
17(9):e0274571.
PMID: 36170336
Main Objective: There is limited information on how patient outcomes have changed during the COVID-19 pandemic. This study characterizes changes in mortality, intubation, and ICU admission rates during the first...
8.
Piasecki T, Smith S, Baker T, Slutske W, Adsit R, Bolt D, et al.
Nicotine Tob Res
. 2022 Sep;
25(6):1184-1193.
PMID: 36069915
Introduction: Available evidence is mixed concerning associations between smoking status and COVID-19 clinical outcomes. Effects of nicotine replacement therapy (NRT) and vaccination status on COVID-19 outcomes in smokers are unknown....
9.
Nolan M, Piasecki T, Smith S, Baker T, Fiore M, Adsit R, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Aug;
32(1):12-21.
PMID: 35965473
Background: There is mixed evidence about the relations of current versus past cancer with severe COVID-19 outcomes and how they vary by patient and cancer characteristics. Methods: Electronic health record...
10.
Hohl S, Shoenbill K, Taylor K, Minion M, Bates-Pappas G, Hayes R, et al.
Nicotine Tob Res
. 2022 Jul;
25(2):345-349.
PMID: 35778237
Introduction: The COVID-19 pandemic disrupted cancer screening and treatment delivery, but COVID-19's impact on tobacco cessation treatment for cancer patients who smoke has not been widely explored. Aims And Methods:...